Clinical trial · Observational
Role of Immunoscore® in Stage II-III Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The proposed study is a bidirectional analytical study, composed of a retrospective and a prospective cohorts. Patients with stage II - III colorectal cancer undergoing oncological surgery will be analyzed. The study will include a convenience sample of 100 individuals. Fifty cases will be included retrospectively and fifty prospectively. The study aims to evaluate the benefit of using the Immunoscore test as a predictor of recurrence in patients with operated stage II-III colon tumors. It will also be evaluated the impact on oncologic decision and costs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Adenocarcinoma | Colon Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunoscore Colon Test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Tumour recurrence
- timeFrame
- 2 years
- description
- Impact of Immunoscore stratification on tumor recurrence at 2 years
Secondary outcomes (7)
- measure
- Disease-free survival (DFS)
- timeFrame
- 5 years
- description
- Impact of Immunoscore stratification on DFS at 5 years
- measure
- Overall survival (OS)
- timeFrame
- 5 years
- description
- Impact of Immunoscore stratification on OS at 5 years
- measure
- DFS acoording tumor side
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Anatomopathological diagnosis of colorectal adenocarcinoma 2. Stage II - III (AJCC 8th edition) 3. Patient undergoing surgery with curative intent Exclusion Criteria: 1. Current or previous diagnosis (within the last 5 years) of another invasive primary malignant neoplasm, with the exception of non-melanoma skin neoplasm 2. Presence of distant metastatic disease evidenced in imaging tests
References
Publications (0)
Data not yet available